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Objtiives. This study sought to assess the usefulness of 
platelet-dependent thmmbin generation as an index rf coagula- 
bility in diabetes and to determine the eRect of glycemic cor:trJ on 
coagulability in diabetes. 
Bac&ground. It is important to investigate the interaction of 
platelets and the coagulation factors to clarify the processes of the 
coagulation system in detail. 
Methods. Platelet-rkb plasma (150 X IOYliter), 0.5 ml, was 
prepared, and 40 mmollliter of calcium chloride was added to 
initiate clotting. S-2238 was added to each sample in a mkrotiter 
plate every 10 min, and the absorbance of the released color 
product at 2 min was measured spectmphotometrkally at a 
wavelength of 405 nm using a q irmtiter plate reader as tbmmbin 
generation. We measured the platr!etdepeodent thrombin gener- 
ation in patients with non-insulin-dependent diabetes mellitus 
grouped aceording to glycemk control. 
Resudrs. Platelet-dependent thmmbio generation at 30 min 
Diabetic angiopathy is classified into microangiopathy. which is 
specific to diabetes mellitus. and macroangiopathy, which is 
not specific to diabetes mellitus but is more common in 
diabetic patients than in the nondiabetic population. Because 
systemic atherosclerosis underlies macroangiopathy, macroan- 
giopathy can cause myocardial infarction or cerebral infarction 
and thus have a significant impact on quality of life and 
survival. Recently, the blood coagulation system has been 
considered to be involved in the etiology of macroangiopathy 
(1). Many investigators have presented data showing that 
diabetic patients have enhanced platelet function (2-9) and 
hypercoagulability (10-18). However, it has also been reported 
that the plasma level of fibrinopeptide A, a direct indicator of 
coagulation, is normal in diabetic patients (19.20) and that the 
plasma level of antithrombin-III is normal (21,22) or increased 
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alter cakium chloride addition was significantly blgher in 23 
patients with poorly glycemic-contmlled non-insulin-dependent 
diabetes mellitus without complications, such as diahetk retinop- 
atby, nephropatby and neuropathy (hemoglobin [Hb] Al, >9.@%) 
than in 46 healthy normal subjects (448 f: 75 vs. 165 + 
28 mU/min, p < 0.001). Thmmbin generation in 31 well controlled 
diabetic patients without complkations (Hb A,, ~9.046) was 
intermediate (240 2 72 mU/min) between those of the poorly 
controlled group and healthy normal sobjects. Platelet-poor 
plasma from diabetk patients increased platelet-dependent 
thmmbin generation in normal subjects. 
Conc/usions. Coagulability is evidently enhanced in patients 
with non-insulin-dependent diabetes mellitus compared with that 
in he&by normal subjects on the basis of sssesslwatsoftbe 
platelet&pef&nt tbrombin genera- and good glgremie eontrd 
may help to come& a h-able state in diabetk patients. 
(J Am cdl cordid 1996;27560-6) 
(3). Thus, no definitive trend has been documented with 
respect to coagulability in diabetes. This lack is thought to be 
because coagulability was assessed using plasma samples in 
all these studies and because coagulation markers such as 
antithrombin-III and thrombin-antithrombin-III complex are 
only indirect indicators of thrombin generation. 
It is known that thrombin generation occurs on the acti- 
vated platelet surface very efficiently, and in turn, small 
amounts of thrombin serve to activate platelets (23). There- 
fore, investigation of thrombin generation on the platelet 
surface appears to be important for understanding the process 
of coagulation, and such measurements may be more useful for 
the investigation of coagulation cascade than the assessment of 
plasma fibrinopeptide A or TAT levels. Aronson et al. (24) 
focused or. this point and developed an experimental system 
for the direct measurement of thrombin generation on plate- 
lets. Measurement of thrombin generation using the assay of 
Aronson et al. appears to be useful for investigating the local 
state of coagulation in the vessels. In the present study, we 
therefore measured thrombin generation by this method in 
diabetic patients classified by the control status of blood 
glucose and assessed the usefulness of platelet-dependent 
thrombin generation as an index of coagulability in diabetes. 
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Table I. Clinical Characteristics al Paticrtts and Normal Suhjccls 
Patient\ H’ith NIDDM 
-_ 
Without Ccmmpkttion~ With Complicationa 
rid (‘mtrd: Pwr C0n1r0l. Gwd <‘0n1r0l: Poor Contrl,l. 
Nmnal Suhjccth Hh A,, ~r9.W; Hh A,, ~‘).(I’; Hh A,, <9.W, Hh A,, zY.11’; Patients With IDDM 
(fly 46) (It = 31) (ll :- 3) (II = 3) (n = 17) (n = X) 
Mulcifcmale 21 2.5 14!17 111 13 !II IS BY 17 
Age o’rl 5x.3 2 1.4 h1.R + 2.1 5x.2 f q,’ -- 62.9 -’ 2.5 fl4.b c 3J 42.x 2 3.6 
Duration of diahctcr (!r) 7.H 2 1.2 0.2 z? 1.3 I3.Y 2 I.4 19.h t 2.5 Il.9 z 3.0 
Rang Oh -3 Oh-?3 O.h-30 .S3? S-3 
Current therapy 
Diet - Ih 5 4 0 n 
Oral hypnglyccmic agents - IS IX IIt 7 0 
Insulin - 0 0 II III x 
Plasma 
FBS (mmol/liter) .5.x 2 n.4 7.5 f 0.h I?.! 2 WI’ 6.2 If Il.3 Y.6 z O.Sf 13.h f 2.4t 
Hh A,, (%) S.8 2 Il.? 7.1 2 0.3 11.3 2 lt.3* 7.0 L Il.? INS f 0.4. H.I 2 n.s 
Chokctrrnl (mmol/litcr) 4.76 + O.16 4.K9 r lI.lh s.04 z n.3l 4.63 It ml 5.06 c 0.35 5.09 2 Il.-Y) 
Trigfyccrido (mmollitcr) I.17 2 0.08 1.10 2 0.w I.19 2 tJ.14 I.14 _+ tt.10 1.44 2 0.19 n.98 2 0.13 
HDL cholcstcrol (mmoblitcr) 1.42 + n.13 1.1 I 2 0.x I.lh + 0.13 1.3 r O.l? 1.19 + II.13 151 _+ 0.m 
l p < 0.01. tp < ll.OS, significantly different from normal whjcctb. Data prcscntcd arc mean value ? SE. range or numhcr of patients. FL%5 = fa\ling hlocnf sugar 
Icvcl; Hh A,< = hcmoglohin A,,: HDL = high density lipnprotcin: IDDM = insulindcfwthnt diabetes mcllitus: NIDDM = non-inwlindcpcmknt diahctes mcllitun 
Methods 
Patients. The present study included 96 patients with non- 
insulin-dependent diabetes mellitus (42 men, 54 women; mean 
[?SD] age 61.6 5 1.4 years, range 18 to 69) (Table I). Diabetes 
was diagnosed according to the World Health Organization 
criteria (25). Fifty-four patients with non-insulin-dependent 
diabetes mellitus had no diabetic complicatkms (e.g., diabetic 
retinopathy. diabetic nephropathy. diabetic neuropathy). and 
42 had one or more diabetic complications. Retinopathy was 
classified as normal, preproliferative retinopathy or prolifera- 
tive retinopathy by an ophthalmologist, and preproliferative or 
proliferative retinopathy was defined as diabetic retinopathy. 
Diabetic nephropathy was defined by the presence of persis- 
tent proteinuria (~0.5 g/day) with increased serum concentra- 
tions of creatinine (>I.8 mg/dl). Diabetic neuropathy was 
defined by the presence of polyneuropathy with a motor nerve 
conduction velocity of the fibular nerve c3Y.3 m/s or absence 
of the Achilles tendon reflex. Patients were classified as having 
either poor (hemoglobin [Hb] A,, ~9.0%) or good glycemic 
control (Hb A,, ~9.0%). The duration of diabetes was longer 
in patients with non-insulin-dependent diabetes mellitus with 
than without complications, but the difference was not signif- 
icant. 
Forty-six healthy nondiabetic subjects matched for age and 
gender served as the normal control group (21 men, 25 women; 
mean 58.3 ? 2.4 years, range 29 to 67). In addition, eight 
patients with insulin-dependent diabetes mellitus (one man, 
seven women mean age 42.8 2 3.6 years, range 16 to 61; Hb 
A,, z-9.0%, two patients: Hb A,, <9.0%, six patients) were 
also studied. Patients with underlying thyroii, renal or liver 
dii; hyperlipiietnia; ischemic heart diseaw; heart fai!ure: 
hypertension; Mammatory disease, and malignancies were 
excluded from both the diabetic and nondiabetic groups. Use 
of drugs that could affect platelet function, blood coagulation 
and lipid metabolism was prohibited during the 2 weeks before 
blood collection. A fasting blood sample was collected at 9 AM 
after the subject had rested for at least 1 h. and thrombin 
generation was measured as descriid later. Smoking was 
prohibited for at least 2 h before blood collection. Fasting 
blood sugar and serum cholesterol, triglyceride and high 
density lipoprotein (HDL) cholesterol levels were also mea- 
sured. In addition, the plasma levels of TAT, plasmin-alpha2 
plasmin-inhibitor complex (PIC) and tissue-plasminogen acti- 
vator t-PA antigen were also determined at the same time. All 
subjects gave written informed COnsent to participate in this 
study. 
Measmmeot afplatekt~t tluwdh geocrah 
Thrombin generation was measured according to the method 
of Aronson et al. (24), with slight modifications. Venous blood 
was collected into tubes containing sodium citrate (3.8% 
sodium citrate/blood 1:9) and was centrifuged at 1% at 22°C 
for 10 min. Platelet-rich plasma was separated from the upper 
two-thirds of the supematant to avoid the contamination of 
other cells, including monoqtes, after which the residual blood 
was centrifuged at lJO@ for 15 min :o obtain platelet-poor 
plasma. Platelet counts in platelet-rich plasma were deter- 
mined with a Coulter counter (SPlas IV, Coulter Electronics), 
and the platelet concentration was adjusted to 150 X log/liter 
with platelet-poor plasma after absence of contamination by 
other cells had been confirmed. Aliquots of 05 ml platelet-rich 
plasma were placed into round-bottomed pdypropytene tubes 
(12 X 75 mm), and 20 ~1 of 1 n&liter calcium carbonate was 
added tn start clotting. The 10-d of samples were added to 
wells of a micmtiter plate containing 90 4 of 3.8% sodium 
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citrate at IO-min intervals up to 60 min. and the clotting time 
was determined for each sample. The clotted platelet-rich 
plasma sample changed to a spherical clot floating in the 
plasma on gentle vortex mixing, and the liquid sample could be 
readily aspirated. After completion of the sample addltm. 
SO /.d of 0.5 mmol/liter S-2238 (H-o-Phe-Arg-NH-NO,-‘HCI. a 
thrombin-specific substrate; Daiichi Kagaku Yakuhin) in 
1 mol/liter Tris, pH 8.1, was added, and the absorbance of the 
released color product at 2 min after the addition of S-2238 
was measured spectrophotometrically at a wavelength of 
405 nm using a Vmax microtiter plate reader (Easy Reader, 
EAR 34OAT. SLT Labinstruments GmbH). Measurements at 
each time point were performed in triplicate. The amounts oi 
thrombin generated were calculated from 4 standard curve for 
thrombin. 
Elect of glucose on platelet-dependent thrombin genera- 
tion in normal subjects. n‘he effect of glucose on thrombin 
generation was investigated by measuring rhe platelet- 
dependent thrombin generrtion after incubating platelet-rich 
plasma obtained from normal subjects (n = 8. fasting blood 
sugar 4.6 to 5.7 mmol/liter) with various concentrations of 
glucose for 3 h. Glucose (dextrose, Ohtsuka Pharmaceutical 
Co. Ltd.) was dissolved in physio!ogic saline and added to th; 
platelet-rich plasma of the normal subjects at final concentrs- 
(ions of 5.6, 11.1 and 22.4 mmol/liter. Physiologic saline was 
used as the control. 
Ekt tiplasma from patients with nou-insulin-dependent 
diabetes mellitus on plateletdependent tbrombin generation 
in nor-l subjects. Effects of platelet-poor plasma from pa- 
tients with non-insulin-dependent diabetes mellitus without 
complications and from normal subjects on the platelet- 
dependent thrombin generation in normal control subjects 
were examined. The platelet concentration of platelet-rich 
plasma from each of the normal control subjects (n = 18) was 
adjusted to 150 X log/liter, with platelet-poor plasma from 
each of the normal control subjects plus platelet-poor plasma 
from one patient with non-insulin-dependent diabetes mellitus 
or normal subject (Hb Al, ?9.0%, n = 6; Hb A,, <9.00/o. n = 
6; normal subjects, n = 6). The volume ratio of platelet-poor 
plasma from the patients with non-insulin-dependent diabetes 
mellitus and normal subjects in the control platelet-rich plasma 
was adjusted to 30% and 70%. The platelet-rich plasma from 
normal control subjects without exogenous platelet-poor 
plasma served as the control. The platelet-dependent thrombin 
generation in the normal control subjects was measured in 18 
different experiments. 
Assay of plasma TAT, PIC and t-PA antigen. Plasma TAT 
and PIC levels were determined by enzyme immunoassay using 
commercially available kits (Enzygnost-TAT, Behringwerke 
AG, and PIG-test). Plasma t-PA antigen was determined by a 
solid-phase enzyme immunoassay using a commercially avail- 
able kit (ELISA-tPA, Technoclone). 
Statistical analysis. Statistical analysis was performed us- 
ing repeated-measures analysis of variance for comparing 
thrombii generation. When a difference of p < 0.05 was shown 
by this procedure, multigroup comparison was performed at 
each time point using the Bonferroni method. The Student I 
test was used for the other analysis in the present study. A 
probabilrty value <0.05 was considered statistically significallt. 
These statistical calculations were performed using StatView-J 
(vcrslon 4.02. Abacus C’oncepts, Inc.). Rcrults are expressed as 
mean value z SE. 
Results 
. . Chnlcal variabl-;. The fasting blood sugar and Hb A,, 
levels were signifiLantly higher in the poorly controlled non- 
insulin-dependent diabetes mellitus groups with or without 
complications than in the well controlled groups and the 
healthy group. However, no significant differences among 
these groups were noted with regard to the serum levels of 
total cholesterol, triglycerides or HDL cholesterol (Table 1). 
Platelet-dependent thrombia generation in patients with 
non-insulin-dependent diabetes mellitus witbout diabetic 
complications. The clotting time measured in platelet-rich 
plasma (Fig. IA) was significantly shorter (p < 0.05) in both 
diabetic groups without complications than in the healthy 
group (Table 2). although there was no significant difference 
between the patients with good and poor glycemic control. The 
data for thrombin generation in platelet-rich plasma for each 
diabetic group without complications are shown in Fig. IA. 
Thrombin generation revealed the greatest level in the poorly 
controlled diabetic group, followed by the well controlled 
diabetic group and the healthy group. and the differences 
among the three groups were statistically significant (p < 
0.001). Multigroup comparisons of thrombin generation dem- 
onstrated a significant difference between the poorly con- 
trolied diabetic group and the healthy group (p < 0.001) and 
between the well and poorly controlled diabetic groups (p < 
0.01). Concerning the data for each measurement time, throm- 
bin generation was significantly greater in the poorly controlled 
group than in the healthy group from IO min after the addition 
of calcium c.L,io:ide (10 min. p < 0.05; 20 min. p < 0.01; 30 min, 
p < 0.001; 40 min, p < 0.001; 50 min, p < 0.001; 60 min, p < 
0.001). In thc poorly controlled diabetic group, thrombin 
generation wti also significantly greater than in the well 
controlled group from 10 min after the addition of calcium 
chloride (10 min. p < 0.05; 20 min, p < 0.05; 30 min, p < 0.05; 
40 min, p < 0.01) (Fig. IA). The well controlled group was 
divided into subgroups with an Hb A,, ~7.5% and 7.5% to 
Y%, and the clotting time and thrombin generation were 
compared between these subgroups. This comparison showed 
no significant difference between the two subgroups. 
Plateletdepeudeut tbrombio generatiw iu patients with 
non-insulindepeudent diabetes mellitus witb complkations. 
Clotting time was significantly shorter (p < 0.05) in the poorly 
controlled diabetic group with complications (Fig. IB) than in 
the healthy group (Table 2). although there was no significant 
difference between the well controlled diabetic patients with 
complications and the healthy group. Thrombm generation 
achieved the greatest level in the poorly controlled diabetic 
group with complications, followed by the well controlled 
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Fiire 1. Platelet-dependent thrombin generation in patients with 
non-insulin-dependent (NIDDM) and insulin-dependent diabetes 
mellitus (IDDM). A Thrombin generation revealed high levels in 
patients with poorly controlled non-insulin-dependent diabetes melli- 
tus without complications compared with those in normal subjects, but 
its value was closer to that in normal control subjects and in patients 
with well controlled non-insulin-dependent diabetes mellitus without 
complications. B, Thrombin generation was also greatest in patients 
with poorly controlled non-insulin-dependent diabetes mellhus with 
complications and intermediate in patients with well controlled non- 
insulin-dependent diabetes mellitus with complications, as in the case 
of patients with non-insulin-dependent diabetes mellitus without 
complications. Thrombin generation in patients with insulin- 
dependent diabetes mellitus revealed high levels compared with those 
in normal subjects but was not as high as those in patients with poorly 
controlled non-insulin-dependent diabetes mellitus. Results are shown 
as mean value i: SE. ‘p < 0.05, **p < 0.01, “*p < 0.001, normal 
subjects versus each diabetic group. tp < 0.05, ttp < 0.01. diabetic 
groups with good versus poor control. 
Effect d plasma fhm diabetk patients 011 plstekt- 
depewknt tllmubiu generatiua III aolmal sshjeels. Clotting 
time of platelet-rich plasma from normal subjects was short- 
ened with increasing concentrations of platelet-poor plasma 
from patients with non-insulin-dependent diabetes mellitus 
without complications in both of the two glycemic control 
groups but was not affected by platelet-poor plasma from 
normal subjects (Fig. 2). The differences were significant from 
the control in both the well and poorly controlled diabetic 
groups (70% vol) (Fig. 2B,C). Platelet-dependent thrombin 
generation was not alkcted by the addition of platelet-poor 
plasma from normal subjects (Fig. 2A). Thrombm generation 
tended to become higher with increasing doses of platelet-poor 
plasma from patients with Fnt diabetes mel- 
lituscompaxdwithcontisubjec&espe&Uyinthefmorly 
controlledgroup.andtheditferencesweresignikntinboththe 
well and poofly controued diabetic groups (70% vol) (Fii ZBC). 
d;.L.etic group and the healthy group, and the differences Plasma TAT, PIG ad CPA at@ea hhkers of the coag- 
anl$n5 .he three groups were statistically significant (p < ulation and fibrinolysii system were also compared among the 
0.W) (Fig. 1B). Multigroup comparisons of thrombin gener- diabetic groups (Table 2). No significant difference in plasma 
ation demonstrated a significant difference between the poorly TAT levels was noted among these groups. The intergroup 
controlled diabetic group with complications and the healthy 
group (p < 0.001). as in the case of the poorly controlled 
diabetic group without complications and the healthy group. 
However. no significant difference was observed between the 
poorly and well controlled diabetic groups with complications. 
There were no significant differences in thrombin generation 
between the poorly controlled diabetic group with complica- 
tions and that without complications or between well con- 
trolled diabetic patients with and without complications. Con- 
cerning the data for each measurement time. thrombin 
geceration was significantly greater in the poorly controlled 
group than in the healthy group from IO min after the addition 
of calcium chloride (10 min, p < 0.05; 20 min, p < 0.01: 30 min, 
p < 0.05: 40 mb, p < 0.01; 50 min. p K 0.001. 60 min, p < 
0.001). In the well controlled diabetic group, thrombin gener- 
ation was significantly greater than that in the healthy group 
(30 min, p < 0.01; 40 min, p < 0.05; 60 min, p < 0.01) (Fig. 
IB). 
Ptatektdepdent thmbin geueratiua in patknts with 
iosulindependcnt diabetes mellitus. Clotting time and 
thrombin generation in the eight patients with insulin- 
dependent diabetes mellitus were shorter and higher than 
those in the healthy control subjects, respectively. However, 
thrombin generation was not as great as that in the poorly 
controlled di&etic grnup (Fig. 1B). Thrombin generation was 
significantly different between the patients with insulin- 
dependent diabetes mellitus and normal subjects at each time 
point (20 min, p < 0.05; 60 min, p < 0.01) (Fig. IB). 
Ehct of glucose on platektdepemknt tbnmlbin geuem- 
tion in d subjects. When platelet-rich plasma samples 
from normal subjects were preincubated with gluaxe at con- 
centrations of 5.6 to 22.4 mmol/liter for 3 h, clotting time 
tended to be shorter and thrombin generation became higher, 
according to the glucose concentration added, than that in 
control subjects without exogenous glucose (Table 3). 
Clolting lime (min) 1x + 4 34 * 4. 3 ? 4’ 3x 7 7 3-l + S’ 4) -: i 
Pl;bma 
TAT (ng,ml) 2.x z 0.7 3.: + 0.P .’ Y t 11.7 2.11 f 0.: 2,s r l!.S 2,s ? Il.2 
PIG (, t’ml) 0.77 f O.llY MI : 1!.11) Il.iX : OW lJ.711 L 0. I I II.75 f ILlI Il.xll t 0.0s 
I-PA .m@n (@ml) 2.7 2 Il.4 3.n + IL.5 2.1 2 0.4 2.7 f IL> 2,s z 0.: 2.1, 2 0.1 
‘p C: 11.05. rignikcundy ditfcrcn~ from normal subject\. Ma prcscnkd arc mean voluc f SE. PIG = plarmin-alpha, pla\mm inhihilor; TAT := thromhin- 
antithrtrmhin-Ill complex: I-PA = liaauc-ypc plavninogcn activalor olhcr &brcviaCons a\ in Tahlc I. 
differences were also not significant for plasma PIC levels. The 
t-PA antigen levels were slightly lower in the poorly controlled 
grotlp without complications than in the healthy group. hut 
again there were no significant intergroup differences. 
Discussion 
It is generally agreed that coagulability is more or less 
enhanced in diabetes mellitus (10-18). In the present study, 
platelet-dependent thrombin generation was measured in dia- 
betic patients with good and poor glycemic control. Signifi- 
cantly increased thrombin generation was found in both di+ 
betic groups compared with that in healthy subjects. 
Signiftcance of measurement of platelet-dependent throm- 
bin generation. A decreased plasma level of antithrombin-III 
(10,11,13), which is reported to result from nonenzymatic 
glycosylation, and an increased plasma level of TAT (16-18) 
have been reported as indicators of hypercoagulability in 
diabetes. However, opposing data have a!so been published 
(3,9-22), and there is no consensus as yet. This lack of 
consensus may be partly because coagu!a!ion markers are 
assayed in ordinary plasma rather than in platelet-rich plasma. 
Thrombus formation proceeds as a result of interactions 
between platelets and the coagulation system. Briefly, coagu- 
lation factor X generation occurs on the activated platelet 
surfaces, and platelet factor III accelerates the conversion of 
prothrombin to thrombin (26.27). Activation of coagulation 
factor X1 on the platelet surface is considered to trigger the 
coagulation cascade (28). The small amounts of thrombin 
Table 3. Effects of Glucose on Clotting Time and Platelet- 
Dependent Thrombin Generation in Normal Subjects* 
Glucose Added Clotring Time Thromhin Gencratlvn 30 min Afkr 
(mmol/litcr) (min) Calcium Chloride Added (mUmin) 
(I 46?7 98 2 16 
5.6 45 + 4 122 z 22 
11.1 38 2 4 178 + 35t 
22.4 36 2 St 185 2 24t 
*Platelet-rich plasma in normal subjects was preincubated with glucose for 
3 h. tp < 0.05, signilicandy different fmm control without exogenous glucose. 
Data presented arc mean value ? SE. 
generated during the ccagulation cascade serve 10 activate 
platelets and stimulate the release of coagulation factor Va 
from the alpha-granules. Coagulation factor Va forms a com- 
plex with activated coagulation factor X, and thrombir, is thus 
generated very efficiently and quickly on the activated Dlatelet 
surface. Thus, platelets and thrombin act complemenlarily in 
the process of thrombus formation, and the coagulatian cas- 
cactr is thoughi to be remarkably augmented on the platelet 
membrane (23). Therefore, measurement of thrombin gener- 
ation in platelet-rich states, as was performed in the present 
study, is thought to provide more accurate data concerning the 
coagulation system. Because thrombin binds not only to 
antithrombin-Ill but also to heparin cofactor II and thrombo- 
modulin, TAT is a less than perfect indicator of thrombin 
generation. Thus. coagulation markers such as antithrombin- 
III and TAT are only indirect indicators of thrombin genera- 
tion. Plasma TAT levels in the diabetic patients assessed in the 
present study did, in fact, vary widely, and there were no 
significant intergroup differences. Measurement of platelet 
surface thrombin activity may therefore be more useful for the 
investigation of coagulation. The results of the present study 
clearly confirmed the existence of hypercoagulability in dia- 
betic patients. 
Clinical implicatiow In the present study, the clotting 
time and platelet-dependent thrombin generation were as- 
sessed separately in groups with good and poor glycemic 
control on the basis of Hb A,, levels: The results in the well 
controlled diabetic group were intermediate, regardless of 
whether complications were present or not, behveen that of the 
poorly controlled group and the healthy subjects, suggesting 
normalization of clotting time and thrombin activity by improv- 
ing glycemic control. A significant difference in thrombin 
generation was observed between the poorly and well con- 
trolled diabetic groups without complications, but there was no 
significant difference between the poorly and well controlled 
diabetic patients with complications. It is possible that diabetic 
patients with complications might possess some unknown 
factors that can affect thrombin generation, and this could 
result in no significant difference in thrombin generation 
between poor and good glycemic control. Diabetic patients 
with complications may thus not be appropriate study patients 
0 
0 10 2030405000 
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for investigating thrombin generation in diabetes mellitus. 
There arc few studies that have classified diabetic patients by 
their level of glycemic control and assessed various coagulation 
markers (12,17). Small et al. (12) reported that fibrinopeptide 
A levels were higher in diabetic patients than in nondiabetic 
subjects and that there was an inverse correlation between 
fibrinopeptide A and Hb A,, (12). They suggested that throm- 
bin activity was reduced by better control of diabetes. Accord- 
ing to Van Wersch et al. (17). the TAT level was abnormally 
high in diabetic patients and was higher in the poorly con- 
trolled group than in the well controlled group Hb A,, >90% 
and <lo%, respectively). The present study yielded data 
consistent with these reports for platelet-dependent thrombin 
activity. These findings suggested that good glycemic control 
may lead to the inhibition of a hypercoagulabie state in 
diabetic patients. 
Idmitatiuns uf the study. There are several limitations to 
the present study. 
1. We did not investigate the effects of obesity on thrombin 
generation, although we excluded subjects with other un- 
derlying diseases in both groups of diabetic patients. Many 
recent studies (B-33) have suggested involvement of the 
coagulation system in hyperlipidemia, one of the risk factors 
for atherosclerosis, and considerable data are available 
showing enhanced platelet function and hypercoagulability 
in patients with hyperlipidemia. We also investigated 
plateletdependent thrombii generation in patients with hy- 
perlipidemia and found thut thro&iu geueration was in- 
creased, as it is in diabetic patients (unpublished obwwtiom). 
However, only diabetk patients without hyperbp&mia were 
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Figure 2. Effect of platele&poor plasma (PPP) horn patients with 
non--insulin-dependent diabetes mel!itus (NIDDM) oa platelet- 
dependent thromhin generation in normal subjects. A, Clotting time 
and platelet-dependent thrombin generation were unaffected by the 
addition of platelet-poor plasma obtained from normal subjects 
(N-PPP) (n = 6). Band C, Clotting time and thrombin generation were 
shorter and higher. respectively, in accordance with increasing concen- 
!rations of platelet-poor plasma obtained from pabents with non- 
insulin-dependent diabetes mellitus (DM-PPP) (B. Hb A,, 
c9.05. n = 6; C, Hb A,, s9.05;. n = 6). Results shown are mean 
value -C SE. *p < 0.05 “p < 0.01, significantly different from control. 
enrolled in the present study, so the possibility of an effect of 
hyperlipidemia on thrombin generation can be ruled out. 
2. Patients with non-insulin-dependent diabetes mellitus in 
the present study were obtained randomly and classilied 
into two groups by Hb A,, levels. Platelet-dependent 
thrombin generation should be compared in the same 
diabetic patients before and after achievement of glycemic 
control. Such investigations may provide more accurate 
assessment in coagulability in diabetic patients. 
3. ‘“e failed to find any significant difference between the well 
and poorly controlled diabetic patients regarding platelet- 
dependent thrombin generation at ~50 min after calcium 
chloride addition, showing the total extent of prothrombin 
activation to be unchanged. This may reflect the extent of 
coagulation factor XaWa activity. 
4. We failed to detect higher levels of thrombm generation in 
patients with insulindependent diabetes mellitus compared 
with tbose in patients with poorly controlled non-inwiin- 
dependent diabetes mellitus This linding e K&C& 
the good glpnic amtrol in insulindependeut diabetes 
mellihs in the present study. 
shh AOKI tT AL 
DI.\YETIC PIA1T:Lr.T.Dl:PIINDl:NI TIIROMBlh PRtIIX~-TIOS 
S. We were unable to evaluate the mechanism of hypercoagu- 
lability in non-insulin-dependent diabetes mcllitus. In the 
present study, thromhin generation in platelet-rich plasma 
from normal subjects tended to he increased with increasing 
doses of platelet-poor plasma from patients with non- 
insulin-dependent diabetes mellitus in both the well and 
poorly controlled grobpa These findings suggest that hyper- 
coagulability in non-itxolin-dependent diabetes mellitus 
could result from certain plasma factors in non-insulirt- 
dependent diabetes meltitus. We were unable to identify 
stimulatory or inhibitory effects of metabolites. such as 
insulin, uric acid or kynurenic acid. the levels of which are 
variable in diabetic patients, on the plateletdependent 
thrombin generation in normal subjects (data arc not 
shown). However. thrombin generation in platelet-rich 
plasma from normal subjects was stimulated by the ad- 
dition of glucose in vitro. so that the higher levels of 
thrornbin generation occurring in patients with non-insulin- 
dependent diabetes mellitus are presumably related in part 
to some direct action of glucose. Moreover. it is possible 
that diabetic patients possess some type of factor that can 
facilitate coagulability. although the details remain unclear 
at present. 
Conelusiorls. Determination of platelet-dependent throm- 
bin generation suggested that coagulability was enhanced in 
diabetic patients compared with that in healthy subjects. 
Enhanced thrombin generation may be one reason for the 
progression of atherosclerosis. The present study also showed 
that thrombin generation can be reduced by good control of 
blood glucose. Therefore, our results suggest that good glyce- 
mic control is important for prevention of atherosclerosis and 
thrombosis and may also improve the overall prognosis of 
patients with diabetes. 
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